French and South Korean Drugmakers Partner to Develop Single-Shot Universal Flu Vaccine

2026-08-28 companies

Lyon, Friday, 28 August 2026.
Osivax and GC Biopharma have partnered to co-develop a single-injection flu vaccine offering broader, longer-lasting immunity by targeting both surface and internal viral proteins.

Strategic Collaboration Announced

French biopharmaceutical firm Osivax and South Korea’s GC Biopharma (006280.KS) formally announced a long-term collaboration on 2026-08-26 to co-develop a next-generation seasonal influenza vaccine [1][5]. The partnership aims to combine Osivax’s broad-spectrum nucleoprotein candidate OVX836 with GC Biopharma’s established GC FLU platform to create a vaccine with enhanced universal protection against multiple seasonal and pandemic flu strains [1][4]. This strategic move was further detailed in announcements made on 2026-08-27 and 2026-08-28, highlighting the urgency and significance of the alliance in the current pharmaceutical landscape [2][6]. Osivax, while a key player, does not have a publicly listed ticker symbol available in the provided documentation [alert! ‘Osivax ticker not provided in sources’].

Mechanism and Clinical Background

The core of this collaboration lies in the complementary immune responses generated by the two candidates. OVX836 targets the conserved nucleoprotein (NP) to induce T-cell responses, while GC FLU targets Hemagglutinin surface antigens to trigger antibody responses [3][4]. This dual mechanism is designed to overcome the limitations of current flu vaccines that primarily target variable surface antigens, which require frequent updates due to mutation [3]. OVX836 has already been tested in seven clinical trials with more than 4,000 participants, showing promising safety and efficacy data [5]. Previous research in a Phase 2a trial demonstrated good tolerability and generation of hemagglutinin and nucleoprotein immune responses when co-administered with GSK’s Fluarix Tetra [2].

Strategic Division of Rights and Responsibilities

Under the agreement, Osivax receives a non-exclusive, sublicensable, global license to use GC FLU in combination with OVX836, excluding Japan and Korea, where GC Biopharma retains exclusive rights and will receive royalties [1]. Osivax will lead global development and commercialization of the combination vaccine outside the Republic of Korea, while GC Biopharma is responsible for the long-term supply of GC FLU [1][4]. This structure allows GC Biopharma to secure a diversified profit model while reinforcing its domestic position in the Republic of Korea [6]. Financial terms of the agreement were not disclosed to the public [5].

Development Timeline and Milestones

Osivax finished enrolling 2,850 participants in the Phase 2b efficacy study of OVX836 in December 2025 and projected topline results by mid-2026 [2]. As of 2026-08-28, the status of these topline results is considered overdue based on the initial projection [2]. The OVX836-002 Phase IIA trial, conducted at the Centre for Vaccinology in Ghent, Belgium, previously enrolled 300 healthy adults between December 2019 and September 2020, with results published in April 2022 [1]. This new partnership marks a key step towards developing a superior seasonal influenza vaccine by combining Osivax’s T-cell-focused approach with GC Biopharma’s manufacturing capabilities [1].

Market Implications and Financial Context

The global flu vaccine market is expected to grow from $9.2 billion in 2025 to $22.5 billion in 2034, representing a significant expansion opportunity [6]. The calculated growth rate of the market over this period is 144.565 percent [6]. GC Biopharma Corp. has traded between KRW 126,900 and KRW 183,800 over the past year, with the stock currently trading at KRW 127,100, down 2.61% [5]. This collaboration supports GC Biopharma’s continued expansion into major advanced markets while reinforcing its domestic position [1]. The demand for unmet general-purpose next-generation vaccines is high, so commercialization is expected to have a great impact on the global market [6].

Challenges in Universal Vaccine Development

Historical context suggests caution, as BiondVax’s M-001 universal influenza vaccine candidate failed a Phase 3 clinical trial, showing no significant reduction in influenza illness compared to placebo [2]. Despite decades of progress in influenza vaccination, there remains a significant need for approaches that can provide broader and more durable protection against evolving influenza strains [1]. Executives from both companies emphasized that the collaboration represents a key step toward addressing long-standing unmet needs in influenza prevention [5]. Seasonal influenza continues to pose a significant public health burden, particularly among older adults and vulnerable populations [5].

Sources

Flu Vaccine Pharma Partnership